IL300364A - immunogenic substances - Google Patents
immunogenic substancesInfo
- Publication number
- IL300364A IL300364A IL300364A IL30036423A IL300364A IL 300364 A IL300364 A IL 300364A IL 300364 A IL300364 A IL 300364A IL 30036423 A IL30036423 A IL 30036423A IL 300364 A IL300364 A IL 300364A
- Authority
- IL
- Israel
- Prior art keywords
- asyn
- disease
- peptide
- amino acid
- antigenic peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20189425 | 2020-08-04 | ||
| PCT/EP2021/071778 WO2022029181A1 (en) | 2020-08-04 | 2021-08-04 | Immunogenic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300364A true IL300364A (en) | 2023-04-01 |
Family
ID=72178339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300364A IL300364A (en) | 2020-08-04 | 2021-08-04 | immunogenic substances |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287050A1 (enExample) |
| EP (1) | EP4192493A1 (enExample) |
| JP (1) | JP2023536497A (enExample) |
| KR (1) | KR20230044524A (enExample) |
| CN (1) | CN116261464A (enExample) |
| AU (1) | AU2021322080A1 (enExample) |
| CA (1) | CA3185563A1 (enExample) |
| IL (1) | IL300364A (enExample) |
| MX (1) | MX2023001483A (enExample) |
| WO (1) | WO2022029181A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240147981A (ko) * | 2022-02-09 | 2024-10-10 | 에이씨 이뮨 에스에이 | 항-알파시누클레인 치료 백신 |
| AU2024211543A1 (en) | 2023-01-26 | 2025-07-17 | Ac Immune Sa | Liposomal construct |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2361928T3 (pl) | 2003-05-19 | 2017-09-29 | Prothena Biosciences Limited | Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego |
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| SI2723379T1 (sl) * | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| RU2734924C2 (ru) | 2015-11-03 | 2020-10-26 | Аффирис Аг | Способ вакцинации против аутоантигена у пациента-человека |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| EP3638298A4 (en) * | 2017-06-16 | 2021-05-05 | United Neuroscience | PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA |
| US20230074436A1 (en) * | 2019-09-20 | 2023-03-09 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
-
2021
- 2021-08-04 CA CA3185563A patent/CA3185563A1/en active Pending
- 2021-08-04 KR KR1020237007745A patent/KR20230044524A/ko active Pending
- 2021-08-04 JP JP2023507480A patent/JP2023536497A/ja active Pending
- 2021-08-04 US US18/014,846 patent/US20230287050A1/en active Pending
- 2021-08-04 EP EP21758636.1A patent/EP4192493A1/en active Pending
- 2021-08-04 CN CN202180050068.9A patent/CN116261464A/zh active Pending
- 2021-08-04 MX MX2023001483A patent/MX2023001483A/es unknown
- 2021-08-04 IL IL300364A patent/IL300364A/en unknown
- 2021-08-04 WO PCT/EP2021/071778 patent/WO2022029181A1/en not_active Ceased
- 2021-08-04 AU AU2021322080A patent/AU2021322080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3185563A1 (en) | 2022-02-10 |
| WO2022029181A1 (en) | 2022-02-10 |
| KR20230044524A (ko) | 2023-04-04 |
| CN116261464A (zh) | 2023-06-13 |
| JP2023536497A (ja) | 2023-08-25 |
| EP4192493A1 (en) | 2023-06-14 |
| AU2021322080A1 (en) | 2023-02-23 |
| MX2023001483A (es) | 2023-03-08 |
| US20230287050A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230201320A1 (en) | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy | |
| US8828942B2 (en) | Means for treating synucleinopathies | |
| KR20110036808A (ko) | 베타-아밀로이드증을 치료하기 위한 화합물 | |
| US20230287050A1 (en) | Immunogenic Compounds | |
| US20070172496A1 (en) | Conjugates of amyloid proteins as vaccines for amyloid-related diseases | |
| US20150306194A1 (en) | Method for treating a synucleiopathy | |
| US20250152684A1 (en) | Anti-Alpha-Synuclein Therapeutic Vaccines | |
| TW202438516A (zh) | TAU及β類澱粉肽免疫原組合物及相關方法 | |
| EA048154B1 (ru) | Иммуногенные соединения | |
| HK40087814A (zh) | 免疫原性化合物 | |
| TW202142551A (zh) | 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑 | |
| EA051687B1 (ru) | Терапевтические вакцины против альфа-синуклеина | |
| CN118660717A (zh) | 抗α-突触核蛋白的治疗性疫苗 | |
| EP4554618A2 (en) | Tau peptide immunogen constructs |